Impel NeuroPharma, Inc. Company Profile

04:11 EDT 27th June 2019 | BioPortfolio

Impel NeuroPharma, Inc. is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel NeuroPharma has developed a novel drug delivery platform, the POD™ technology, that administers drug to the deep nasal cavity to improve the biodistribution of many drugs. Impel NeuroPharma’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma please visit our website:

News Articles [9 Associated News Articles listed on BioPortfolio]

Biotech startup Impel NeuroPharma raises $67.5M

Impel NeuroPharma, a startup working on ways to deliver medications to the brain more efficiently than current methods, raise -More- 

Impel Neuropharma reports positive results from Phase I INP105 trial

Impel NeuroPharma has reported positive results from the SNAP 101 Phase I trial evaluating the safety and tolerability of INP105...Read More... The post Impel Neuropharma reports positive results from...

Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute ...

SEATTLE, Jan. 6, 2019 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on innovative therapies for the treatment of central nervous system (CNS) Re...

Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio

Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million. It was co-led by KKR and Northwest Venture Partners. Existing investors Vivo Capital, 5AM Ventures and venBio Par...

Impel Raises $67.5M to Advance Intranasal Drugs for CNS Disorders

Impel NeuroPharma, which is developing technology to deliver certain therapeutics more effectively to the brain, says it has raised $67.5 million in new funding to support clinical trials of its drug ...

Impel NeuroPharma raises $67.5mm through Series D round

Impel NeuroPharma Inc. (intranasal treatments for CNS disorders) raised $67.5mm through a Series D round co-led by KKR and Norwest Venture Partners (both added board members), which were joined by ret...

#news #biotech Impel raises $67.5M as it eyes filing for nasal migraine drug

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Impel raises $67.5M as it eyes filing for nasal migraine drug .Impel NeuroPha...

Neuropharma: A New Wave of Drugs to Treat Alzheimer’s Disease

In this interview, Fintan Walton speaks with Belén Sopesén, Managing Director of Neuropharma, a subsidiary of the Zeltia group specialising in research and development of innovative drugs for the tr...

Drugs and Medications [0 Results]


PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD ) Device, in Healthy Adult Subjects.

Investigate the safety and pharmacokinetics (PK) of INP104, intranasal dihydroergotamine mesylate (DHE) administered via a Precision Olfactory Delivery (POD ) device, (Impel NeuroPharma, Seattle, WA) ...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Study of Nasal Insulin to Fight Forgetfulness - Device Comparison Study

The SNIFF Device Comparison study will compare the ability of two devices that deliver medications through the nose (Kurve ViaNase device and Impel Precision Olfactory Delivery (POD) devic...

Companies [4 Associated Companies listed on BioPortfolio]

Impel NeuroPharma, Inc.

Impel NeuroPharma, Inc. is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel NeuroPharma has developed a novel drug d...

Impel NeuroPharma Inc.

Impel NeuroPharma Inc. is a biopharmaceutical company specializing in developing enhanced CNS products based on its proprietary Precision Olfactory Delivery (POD) technology.

Impel NeuroPharma

Based in Seattle, WA, Impel NeuroPharma is a medical device company whose Pressurized Olfactory Delivery technology enables pharmaceutical drugs to bypass the blood-brain barrier ...

Maas Biolab, Inc.

Maas Biolab is a neuropharmaceutical company developing a treatment- the use of cyclosporins as neuro-protectants- for chronic neurodegenerative diseases including amyotrophic lateral sclerosis, Alzhe...

More Information about "Impel NeuroPharma, Inc." on BioPortfolio

We have published hundreds of Impel NeuroPharma, Inc. news stories on BioPortfolio along with dozens of Impel NeuroPharma, Inc. Clinical Trials and PubMed Articles about Impel NeuroPharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Impel NeuroPharma, Inc. Companies in our database. You can also find out about relevant Impel NeuroPharma, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Corporate Database Quicklinks

Searches Linking to this Company Record